Allosteric conversation in the androgen receptor ligand-binding domain surfaces

Molecular Endocrinology

Volumn 26, Issue 7, 2012, Pages 1078-1090

  Grosdidier, Solène ^a   Carbó, Laia R ^b   Buzón, Víctor ^b   Brooke, Greg ^d   Nguyen, Phuong ^c   Baxter, John D ^c   Bevan, Charlotte ^d   Webb, Paul ^c   Estébanez Perpiñá, Eva ^b   Fernández Recio, Juan ^a  

^a BARCELONA SUPERCOMPUTING CENTER   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION FUNCTION 2 PROTEIN; AMINO TERMINAL TELOPEPTIDE; ANDROGEN RECEPTOR; BINDING FUNCTION 3 PROTEIN; BINDING PROTEIN; COREPRESSOR PROTEIN; LIGAND; NUCLEAR RECEPTOR COACTIVATOR; UNCLASSIFIED DRUG;

ALLOSTERISM; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; CONTROLLED STUDY; CROSS COUPLING REACTION; CRYSTAL STRUCTURE; DRUG DESIGN; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; X RAY CRYSTALLOGRAPHY;

ANDROGEN-INSENSITIVITY SYNDROME; BINDING SITES; CELL LINE, TUMOR; HELA CELLS; HUMANS; LIGANDS; MALE; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MUTATION; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANDROGEN;

EID: 84863336768     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2011-1281     Document Type: Article

References (72)

1. Lubahn DB, Joseph DR, Sar M, Tan J, Higgs HN, Larson RE, French FS, Wilson EM 1988 The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol 2:1265-1275
2. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Ume-sono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM 1995 The nuclear receptor superfamily: the second decade. Cell 83:835-839
3. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH 1991 Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77-79
4. Quigley CA, French FS 1994 Androgen insensitivity syndromes. Curr Ther Endocrinol Metab 5:342-351
5. Brinkmann A, Trapman J 2000 Genetic analysis of androgen receptors in development and disease. Adv Pharmacol:317-341.
6. Brinkmann AO 2001 Molecular basis of androgen insensitivity. Mol Cell Endocrinol 179:105-109
7. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD 2001 Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 7:1273-1281
8. Gottlieb B, Beitel LK, Wu J, Elhaji YA, Trifiro M 2004 Nuclear receptors and disease: androgen receptor. Essays Biochem 40:121- 136
9. Hughes IA, Deeb A 2006 Androgen resistance. Best Pract Res Clin Endocrinol Metab 20:577-598
10. Brooke GN, Bevan CL 2009 The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 10:18-25
11. Tindall DaM, Mohler J, eds. 2009 Androgen action in prostate cancer. ISBN 978-0-387-69177-0
12. Knudsen KE, Penning TM 2010 Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends En-docrinol Metab 21:315-324
13. Szafran AT, Sun H, Hartig S, Shen Y, Mediwala SN, Bell J, McPhaul MJ, Mancini MA, Marcelli M 2011 Androgen receptor mutations associated with androgen insensitivity syndrome: a high content analysis approach leading to personalized medicine. Adv Exp Med Biol 707:63-65
14. Jenster G, van der Korput HA, van Vroonhoven C, van der Kwast TH, Trapman J, Brinkmann AO 1991 Domains of the human an-drogen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 5:1396-1404
15. Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S, Otto N, Joschko S, Scholz P, Wegg A, Bäsler S, Schäfer M, Egner U, Carrondo MA 2000 Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 275:26164-26171
16. Heery DM, Kalkhoven E, Hoare S, Parker MG 1997 A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733-736
17. He B, Kemppainen JA, Wilson EM 2000 FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem 275:22986-22994
18. Christiaens V, Bevan CL, Callewaert L, Haelens A, Verrijdt G, Rombauts W, Claessens F 2002 Characterization of the two coacti-vator-interacting surfaces of the androgen receptor and their relative role in transcriptional control. J Biol Chem 277:49230-49237
19. Hur E, Pfaff SJ, Sturgis PE, Hanne G, Buehrer BM, Fletterick RJ 2004 Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol 2:E274
20. Estébanez-Perpiñá E, Moore JM, Mar E, Delgado-Rodrigues E, Nguyen P, Baxter JD, Buehrer BM, Webb P, Fletterick RJ, Guy RK 2005 The molecular mechanisms of coactivator utilization in li-gand-dependent transactivation by the androgen receptor. J Biol Chem 280:8060-8068
21. Jasuja R, Ulloor J, Yengo CM, Choong K, Istomin AY, Livesay DR, Jacobs DJ, Swerdloff RS, Miksovská J, Larsen RW, Bhasin S 2009 Kinetic and thermodynamic characterization of dihydrotestoster-one-induced conformational perturbations in androgen receptor ligand-binding domain. Mol Endocrinol 23:1231-1241
22. Watanabe C, Watanabe H, Tanaka S 2010 An interpretation of positional displacement of the helix12 in nuclear receptors: preex-istent swing-up motion triggered by ligand binding. Biochim Bio-phys Acta 1804:1832-1840
23. McPhaul MJ 2008 Mechanisms of prostate cancer progression to androgen independence. Best Pract Res Clin Endocrinol Metab 22: 373-388
24. Nacusi LP, Tindall DJ 2009 Androgen receptor abnormalities in castration-recurrent prostate cancer. Expert Rev Endocrinol Metab 4:417-422
25. Gottlieb B, Pinsky L, Beitel LK, Trifiro M 1999 Androgen insensi-tivity. Am J Med Genet 89:210-217
26. Huggins C 1967 Endocrine-induced regression of cancers. Science 156:1050-1054
27. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H 1999 Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 81:242-251
28. Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT 2005 Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA 102:6201-6206
29. Yuan X, Balk SP 2009 Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol 27:36-41
30. Estébanez-Perpiñá E, Arnold LA, Arnold AA, Nguyen P, Rodrigues ED, Mar E, Bateman R, Pallai P, Shokat KM, Baxter JD, Guy RK, Webb P, Fletterick RJ 2007 A surface on the androgen receptor that allosterically regulates coactivator binding. Proc Natl Acad Sci USA 104:16074-16079
31. Axerio-Cilies P, Lack NA, Nayana RS, Chan KH, Yeung A, Leblanc E, Guns E, Rennie P, Cherkasov A 2011 Inhibitors of androgen receptor activation function-2 (AF2) site indentified through virtual screening. J Med Chem 54:6197-6205
32. Estébanez-Perpiñá E, Jouravel N, Fletterick RJ 2007 Perspectives on designs of antiandrogens for prostate cancer. Expert Opin Drug Discov 2:1341-1355
33. Buzón V, Carbó LR, Estruch SB, Fletterick RJ, Estébanez-Perpiñá E 2012 A conserved surface on the ligand binding domain of nuclear receptors for allosteric control. Mol Cell Endocrinol 348:394-402
34. Wang P, Cieplak P, Kollman PA 2000 How well does a restrained electrographic potential (RESP) model perform in calculating con-formational energies of organic and biological molecules? J Com-put Chem 21:1049-1074
35. Case DA, Cheatham III TE, Darden T, Gohlke H, Luo R, Merz Jr KM, Onufriev A, Simmerling C, Wang B, Woods RJ 2005 The Amber biomolecular simulation programs. J Comput Chem 26: 1668-1688
36. Lee B, Richards FM 1971 The interpretation of protein structures: estimation of static accessibility. J Mol Biol 55:379-400
37. Le Guilloux V, Schmidtke P, Tuffery P 2009 Fpocket: an open source platform for ligand pocket detection. BMC Bioinformatics 10:168
38. Schmidtke P, Souaille C, Estienne F, Baurin N, Kroemer RT 2010 Large-scale comparison of four binding site detection algorithms. J Chem Inf Model 50:2191-2200
39. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Mur-thy L, Zhao Y, DiConcini D, Puxeddu E, Esen A, Eastham J, Weigel NL, Lamb DJ 2000 Androgen receptor mutations in prostate cancer. Cancer Res 60:944-949
40. Duff J, Davies P, Watt K, McEwan IJ 2006 Structural dynamics of the human androgen receptor: implications for prostate cancer and neurodegenerative disease. Biochem Soc Trans 34:1098-1102
41. Elo JP, Kvist L, Leinonen K, Isomaa V, Henttu P, Lukkarinen O, Vihko P 1995 Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. J Clin En-docrinol Metab 80:3494-3500
42. Koivisto PA, Schleutker J, Helin H, Ehren-van Eekelen C, Kallion-iemi O-P, Trapman J 1999 Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia. Clin Cancer Res 5:3578-3582
43. Mononen N, Syrjäkoski K, Matikainen M, Tammela TL, Schleutker J, Kallioniemi OP, Trapman J, Koivisto PA 2000 Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene. Cancer Res 60:6479-6481
44. Hyytinen ER, Haapala K, Thompson J, Lappalainen I, Roiha M, Rantala I, Helin HJ, Jänne OA, Vihinen M, Palvimo JJ, Koivisto PA 2002 Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. Lab Invest 82: 1591-1598
45. Koivisto PA, Hyytinen ER, Matikainen M, Tammela TL, Ikonen T, Schleutker J 2004 Germline mutation analysis of the androgen receptor gene in Finnish patients with prostate cancer. J Urol 171: 431-433
46. Yan J, Feng J, Goldman D, Cook Jr EH, Craddock N, Jones IR, Heston LL, Sommer SS 2004 Mutation scanning of the androgen receptor gene in patients with psychiatric disorders reveals highly conserved variants in alcoholic and phobia patients. Psychiatr Genet 14:57-60
47. Wong HY, Hoogerbrugge JW, Pang KL, van Leeuwen M, van Royen ME, Molier M, Berrevoets CA, Dooijes D, Dubbink HJ, van de Wijngaart DJ, Wolffenbuttel KP, Trapman J, Kleijer WJ, Drop SL, Grootegoed JA, Brinkmann AO 2008 A novel mutation F826L in the human androgen receptor in partial androgen insensitivity syndrome; increased NH2-/COOH-terminal domain interaction and TIF2 co-activation. Mol Cell Endocrinol 292:69-78
48. Yong EL, Ng SC, Roy AC, Yun G, Ratnam SS 1994 Pregnancy after hormonal correction of severe spermatogenic defect due to mutation in androgen receptor gene. Lancet 344:826-827
49. Lim J, Ghadessy FJ, Abdullah AA, Pinsky L, Trifiro M, Yong EL 2000 Human androgen receptor mutation disrupts ternary interactions between ligand, receptor domains, and the coactivator TIF2 (transcription intermediary factor 2). Mol Endocrinol 14:1187-1197
50. Dotzlaw H, Moehren U, Mink S, Cato AC, Iñiguez Lluhí JA, Ba-niahmad A 2002 The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol Endocrinol 16: 661-673
51. Imasaki K, Hasegawa T, Okabe T, Sakai Y, Haji M, Takayanagi R, Nawata H 1994 Single amino acid substitution (840Arg3His) in the hormone-binding domain of the androgen receptor leads to incomplete androgen insensitivity syndrome associated with a ther-molabile androgen receptor. Eur J Endocrinol 1:569-574
52. Beitel LK, Kazemi-Esfarjani P, Kaufman M, Lumbroso R, Di-George AM, Killinger DW, Trifiro MA, Pinsky L 1994 Substitution of arginine-839 by cysteine or histidine in the androgen receptor causes different receptor phenotypes in cultured cells and coordinate degrees of clinical androgen resistance. J Clin Invest 94:546-554
53. Melo KF, Latronico AC, Costa EM, Billerbeck AE, Mendonca BB, Arnhold IJ 1999 A novel point mutation (R840S) in the androgen receptor in a Brazilian family with partial androgen insensitivity syndrome. Hum Mutat 14:353
54. Nazareth LV, Stenoien DL, Bingman III WE, James AJ, Wu C, Zhang Y, Edwards DP, Mancini M, Marcelli M, Lamb DJ, Weigel NL 1999 A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1). Mol Endocrinol 13:2065-2075
55. Buchanan G, Yang M, Harris JM, Nahm HS, Han G, Moore N, Bentel JM, Matusik RJ, Horsfall DJ, Marshall VR, Greenberg NM, Tilley WD 2001 Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transac-tivation function. Mol Endocrinol 15:46-56
56. Wang Q, Lu J, Yong EL 2001 Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region. J Biol Chem 276:7493-7499
57. Tahiri B, Auzou G, Nicolas JC, Sultan C, Lupo B 2001 Participation of critical residues from the extreme C-terminal end of the human androgen receptor in the ligand binding function. Biochemistry 40:8431-8437
58. Gelmann EP 2002 Molecular biology of the androgen receptor. J Clin Oncol 20:3001-3015
59. Ong YC, Kolatkar PR, Yong EL 2002 Androgen receptor mutations causing human androgen insensitivity syndromes show a key role of residue M807 in helix 8-helix 10 interactions and in receptor ligand-binding domain stability. Mol Hum Reprod 8:101-108
60. McPhaul MJ 2002 Molecular defects of the androgen receptor. Recent Prog Horm Res 57:181-194
61. Shi XB, Ma AH, Xia L, Kung HJ, de Vere White RW 2002 Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 62:1496-1502
62. Gruber SB, Chen H, Tomsho LP, Lee N, Perrone EE, Cooney KA 2003 R726L androgen receptor mutation is uncommon in prostate cancer families in the United States. Prostate 54:306-309
63. Mazen I, Lumbroso S, Abdel Ghaffar S, Salah N, Sultan C 2004 Mutation of the androgen receptor (R840S) in an Egyptian patient with partial androgen insensitivity syndrome: review of the literature on the clinical expression of different R840 substitutions. J En-docrinol Invest 27:57-60
64. Quigley CA, Tan JA, He B, Zhou ZX, Mebarki F, Morel Y, Forest MG, Chatelain P, Ritzén EM, French FS, Wilson EM 2004 Partial androgen insensitivity with phenotypic variation caused by androgen receptor mutations that disrupt activation function 2 and the NH(2)- and carboxyl-terminal interaction. Mech Ageing Dev 125: 683-695
65. Ledig S, Jakubiczka S, Neulen J, Aulepp U, Burck-Lehmann U, Mohnike K, Thiele H, Zierler H, Brewer C, Wieacker P 2005 Novel and recurrent mutations in patients with androgen insensitivity syndromes. Horm Res 63:263-269
66. Yen JL, Chang KH, Sheu JC, Lee YJ, Tsai LP 2005 Partial androgen insensitivity syndrome with R840H mutation in androgen receptor: report of one case. Acta Paediatr Taiwan 46:101-105
67. Haelens A, Tanner T, Denayer S, Callewaert L, Claessens F 2007 The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. Cancer Res 67:4514-4523
68. Deeb A, Jääskeläinen J, Dattani M, Whitaker HC, Costigan C, Hughes IA 2008 A novel mutation in the human androgen receptor suggests a regulatory role for the hinge region in amino-terminal and carboxy-terminal interactions. J Clin Endocrinol Metab 93: 3691-3696
69. Tanner TM, Denayer S, Geverts B, Van Tilborgh N, Kerkhofs S, Helsen C, Spans L, Dubois V, Houtsmuller AB, Claessens F, Haelens A 2010 A 629RKLKK633 motif in the hinge region controls the androgen receptor at multiple levels. Cell Mol Life Sci 67:1919-1927
70. Marimuthu A, Feng W, Tagami T, Nguyen H, Jameson JL, Fletter-ick RJ, Baxter JD, West BL 2002 TR surfaces and conformations required to bind nuclear receptor corepressor. Mol Endocrinol 16: 271-286
71. Yumoto F, Nguyen P, Sablin EP, Baxter JD, Webb P, Fletterick RJ 2012 2012 Structural basis of coactivation of liver receptor ho-molog-1 by /3-catenin. Proc Natl Acad Sci USA 109:143-148
72. De Leon JT, Iwai A, Feau C, Garcia Y, Balsiger HA, Storer CL, Suro RM, Garza KM, Lee S, Kim YS, Chen Y, Ning YM, Riggs DL, Fletterick RJ, Guy RK, Trepel JB, Neckers LM, Cox MB 2011 Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proc Natl Acad Sci USA 108:11878-11883